Where The Moonshot Meets The Road: Could Biden's Plan Boost Cures Bill?
Executive Summary
Maybe, but Sen. Alexander lists 21st Century Cures-like legislation below education issues on his 2016 priority list.
You may also be interested in...
Biden’s Cancer Initiative May Intensify Industry, Government Collaboration
Drug companies and NIH embrace Vice President’s call for moonshot to cure cancer; Amgen and Celgene join separate coalition to test 60 molecules in combination Phase II studies.
Sarepta’s DMD Gene Therapy Adcomm Likely To Focus On Dystrophin As A Surrogate Endpoint
Cellular, Tissue and Gene Therapies Advisory Committee will weigh whether the increase in dystrophin production seen with SRP-9001 is reasonably likely to predict clinical benefit in Duchenne muscular dystrophy, Sarepta says; agency had previously told the company a panel meeting would not be needed, but it reversed course late in the review.
Pink Sheet Podcast: Medicare Inflation Rebates And Negotiation, Leqembi Reimbursement, US FDA Gene Therapy Chief
Pink Sheet reporter and editors discuss the first round of mandated Medicare inflation rebates and new guidance on price negotiations, consider the VA’s decision to cover the Alzheimer’s drug Leqembi, and the US FDA continuing to search for a cell and gene therapy office leader.